SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Chugai Pharmaceutical Co., Ltd. (CHGCY) trades at a trailing P/E of 0.2, forward P/E of 0.2. Trailing earnings yield is 500.00%, forward earnings yield 526.32%. PEG 0.01 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (100/100, Pass) — P/E is below market average (0.2); PEG ≤ 1.0 — Peter Lynch undervalued (0.01); earnings yield beats bond yields (500.00%).
- Forward P/E 0.2 (down from trailing 0.2) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.01 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 500.00% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income. Forward yield improves to 526.32% as earnings recover.
Overall SharesGrow Score: 88/100 with 5/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — CHGCY
Valuation Multiples
P/E (TTM)0.2
Forward P/E0.2
PEG Ratio0.01
Forward PEG0.17
P/B Ratio0.00
P/S Ratio0.07
EV/EBITDA0.0
Per Share Data
EPS (TTM)$138.25
Forward EPS (Est.)$139.78
Book Value / Share$0.00
Revenue / Share$400.71
FCF / Share$0.00
Yields & Fair Value
Earnings Yield500.00%
Forward Earnings Yield526.32%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$8.16 |
$491.78B |
$53.59B |
10.9% |
| 2017 |
$11.07 |
$534.2B |
$72.71B |
13.6% |
| 2018 |
$14.06 |
$579.79B |
$92.49B |
16% |
| 2019 |
$47.91 |
$686.18B |
$157.56B |
23% |
| 2020 |
$65.27 |
$786.95B |
$214.73B |
27.3% |
| 2021 |
$92.09 |
$999.76B |
$303B |
30.3% |
| 2022 |
$113.79 |
$1.26T |
$374.43B |
29.7% |
| 2023 |
$98.90 |
$1.11T |
$325.47B |
29.3% |
| 2024 |
$117.68 |
$1.17T |
$387.32B |
33.1% |
| 2025 |
$138.25 |
$1.32T |
$455.05B |
34.5% |
